MK-0524

09/15/2012 - "Laropiprant (LRPT) reduces NIF; however, its effects on chronic flushing (>6 months) have not been studied. "
01/01/2012 - "Now an agent laropiprant (LRP) has been developed, which blocks the flushing pathway. "
06/01/2011 - "Laropiprant, when combined with ERN, significantly reduces the incidence of flushing. "
04/15/2010 - "Laropiprant, a selective prostaglandin-2 receptor inhibitor, specifically targets the cascade of events causing the flushing. "
10/01/2009 - "Laropiprant decreases this flushing and has an approval in Europe but not in the United States. "

05/01/2015 - " responses in Chinese patients with dyslipidemia treated with the extended release (ER) niacin/laropiprant combination 1000/20 mg for 4 weeks and then 2000/40 mg for 8 weeks (n = 121, the primary study) or with ER niacin 1500 mg for at least 4 weeks (n = 68, the replication study) were analyzed according to genotypes of DGAT1 rs7003945 T>C and DGAT2 rs3060 T>C polymorphisms.Treatment"
06/29/2014 - "Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia."
04/01/2011 - "Extended-release niacin/laropiprant represents an effective therapeutic option for the treatment of dyslipidemia across a range of patient types."
01/01/2011 - "Laropiprant (LRPT) is being developed in combination with Merck's extended-release niacin (ERN) formulation for the treatment of dyslipidemia. "
03/01/2010 - "Safety of extended-release niacin/laropiprant in patients with dyslipidemia."

01/01/2010 - "Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia."
01/01/2011 - "This review considers the evidence regarding the clinical efficacy of extended-release niacin and the DP1 antagonist laropiprant in the treatment of hypercholesterolemia and mixed dyslipidemias."
01/01/2011 - "Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters."
04/15/2010 - "Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia."
01/01/2009 - "Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia."

11/01/2009 - "Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis."
11/01/2009 - "We sought to investigate the efficacy of the DP1 antagonist laropiprant (alone or with montelukast) in asthma and seasonal AR and explore whether sequence variations in PTGDR are associated with asthma severity. "
11/01/2009 - "For asthma, no significant differences in FEV(1) or asthma symptoms were noted for laropiprant versus placebo or laropiprant plus montelukast vs montelukast (differences between montelukast and placebo: P <or= .001). "
11/01/2009 - "For asthma, in a double-blind crossover study, 100 patients with persistent asthma were randomized to placebo or laropiprant, 300 mg/d for 3 weeks, followed by addition of montelukast, 10 mg/d for 2 weeks. "

05/01/2009 - "Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia."
07/15/2013 - "Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia."